ProActive Investors writes about RespireRx #pharmaceuticals?#lifesciences?#biotech? #respirerx?#healthcareinnovation?#healthcare?#cannabinoids?#pharmaceuticals?#pharma?#CNS?#epilepsy?#pain?#neurology?#sleep?#apnea?#obstructivesleepapnea?#ADHD?#ADD?#neuromodulators?#THC?#dronabinol?#marinol?#ampakines?#gabakines?#CX1739?#CX717?#KRMII81?#SCI?#OSA?#spinalcordinjury?#Psychiatric?#biotechnology?#epilepsy #neuropathicpain #ADHD #jeffmargolis #OTCmarkets #RSPI #pennystocks #arnoldlippa #apnoea
RespireRx Pharmaceuticals Inc.: A Biopharmaceutical Company
生物技术研究
Glen Rock,New Jersey 1,067 位关注者
Leading discovery and development of innovative treatments to combat diseases caused by neuronal signaling disruption
关于我们
RespireRx Pharmaceuticals Inc. is a leader in the discovery and development of medicines for the treatment of psychiatric and neurological disorders, with a focus on treatment options that address conditions affecting millions of people, but for which there are few or poor treatment options, including obstructive sleep apnea (“OSA”), attention deficit hyperactivity disorder (“ADHD”), epilepsy, chronic pain and recovery from spinal cord injury (“SCI”), as well as certain neurological orphan diseases. RespireRx is developing a pipeline of new drug products based on our broad patent portfolios across two distinct drug platforms: Pharmaceutical Cannabinoids. RespireRx is developing dronabinol, ?-9-tetrahydocannabinol (?-9-THC), a synthetic version of the naturally occurring substance in the cannabis plant, for the treatment of OSA, a serious respiratory disorder that impacts an estimated 29.4 million people in the USA, linked to increased risk for hypertension, heart failure, depression, and diabetes. There are no approved drug treatments for OSA. In two Phase 2 clinical trials, dronabinol produced statistically significant improvements in OSA. Neuromodulators. RespireRx is developing a portfolio of revolutionary neuromodulator compounds including AMPAkines, proprietary compounds that positively modulate AMPA-type glutamate receptors to promote neuronal function for the treatment of CNS-driven neurobehavioral and cognitive disorders, such as SCI and ADHD where, in a Phase 2 clinical trial, one of our lead ampakines produced rapid, statistically significant improvement in adult patients with ADHD. GABAkines, positive allosteric modulators (“PAMs”) of the gamma-amino-butyric acid type A (“GABA-A”) receptors, in development for the treatment of epilepsy and other convulsant disorders, as well as chronic pain. Translational studies in human brain tissue obtained from epilepsy patients has validated the anti-epileptic effects of our lead GABAkine.
- 网站
-
https://respirerx.com/
RespireRx Pharmaceuticals Inc.: A Biopharmaceutical Company的外部链接
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 总部
- Glen Rock,New Jersey
- 类型
- 上市公司
- 创立
- 1987
- 领域
- Pharmaceutical、sleep apnea、cannabinoids、neuromodulators、ampakines、dronabinol、biopharmaceutical、cannabis、THC、Respirerx、gabakines、GABA、gluatamate、pain、spinal cord injury、epilepsy、neuronal signaling、ADHD、marijuana和non-opioid analgesic
地点
-
主要
126 Valley Road, Suite C
US,New Jersey,Glen Rock,07452
RespireRx Pharmaceuticals Inc.: A Biopharmaceutical Company员工
动态
-
RespireRx Press Release-Spinal Cord Injury clinical trial with Shirley Ryan AbilityLab - Dept of Defense Grant #pharmaceuticals?#lifesciences?#biotech? #respirerx?#healthcareinnovation?#healthcare?#cannabinoids?#pharmaceuticals?#pharma?#CNS?#epilepsy?#pain?#neurology?#sleep?#apnea?#obstructivesleepapnea?#ADHD?#ADD?#neuromodulators?#THC?#dronabinol?#marinol?#ampakines?#gabakines?#CX1739?#CX717?#KRMII81?#SCI?#OSA?#spinalcordinjury?#Psychiatric?#biotechnology?#epilepsy #neuropathicpain #ADHD #jeffmargolis #OTCmarkets #RSPI #pennystocks #arnoldlippa #apnoea
-
RespireRx Press Release-AMPAkines for bladder control after spinal cord injury #pharmaceuticals?#lifesciences?#biotech? #respirerx?#healthcareinnovation?#healthcare?#cannabinoids?#pharmaceuticals?#pharma?#CNS?#epilepsy?#pain?#neurology?#sleep?#apnea?#obstructivesleepapnea?#ADHD?#ADD?#neuromodulators?#THC?#dronabinol?#marinol?#ampakines?#gabakines?#CX1739?#CX717?#KRMII81?#SCI?#OSA?#spinalcordinjury?#Psychiatric?#biotechnology?#epilepsy #neuropathicpain #ADHD #jeffmargolis #OTCmarkets #RSPI #pennystocks #arnoldlippa #apnoea
-
RespireRx Press Release re program with NINDS of NIH #pharmaceuticals?#lifesciences?#biotech? #respirerx?#healthcareinnovation?#healthcare?#cannabinoids?#pharmaceuticals?#pharma?#CNS?#epilepsy?#pain?#neurology?#sleep?#apnea?#obstructivesleepapnea?#ADHD?#ADD?#neuromodulators?#THC?#dronabinol?#marinol?#ampakines?#gabakines?#CX1739?#CX717?#KRMII81?#SCI?#OSA?#spinalcordinjury?#Psychiatric?#biotechnology?#epilepsy #neuropathicpain #ADHD #jeffmargolis #OTCmarkets #RSPI #pennystocks #arnoldlippa #apnoea
-
RespireRx, CureGRIN Foundation, Champion Charities collaborate on science and philanthropy #pharmaceuticals?#lifesciences?#biotech? #respirerx?#healthcareinnovation?#healthcare?#cannabinoids?#pharmaceuticals?#pharma?#CNS?#epilepsy?#pain?#neurology?#sleep?#apnea?#obstructivesleepapnea?#ADHD?#ADD?#neuromodulators?#THC?#dronabinol?#marinol?#ampakines?#gabakines?#CX1739?#CX717?#KRMII81?#SCI?#OSA?#spinalcordinjury?#Psychiatric?#biotechnology?#epilepsy #neuropathicpain #ADHD #jeffmargolis #OTCmarkets #RSPI #pennystocks #arnoldlippa #apnoea
-
RespireRx Adds New Board Member-Press Release 1-22-24 #pharmaceuticals?#lifesciences?#biotech? #respirerx?#healthcareinnovation?#healthcare?#cannabinoids?#pharmaceuticals?#pharma?#CNS?#epilepsy?#pain?#neurology?#sleep?#apnea?#obstructivesleepapnea?#ADHD?#ADD?#neuromodulators?#THC?#dronabinol?#marinol?#ampakines?#gabakines?#CX1739?#CX717?#KRMII81?#SCI?#OSA?#spinalcordinjury?#Psychiatric?#biotechnology?#epilepsy #neuropathicpain #ADHD #jeffmargolis #OTCmarkets #RSPI #pennystocks #arnoldlippa #apnoea
-
ProActive Writes about RespireRx New Member of the Board #pharmaceuticals?#lifesciences?#biotech? #respirerx?#healthcareinnovation?#healthcare?#cannabinoids?#pharmaceuticals?#pharma?#CNS?#epilepsy?#pain?#neurology?#sleep?#apnea?#obstructivesleepapnea?#ADHD?#ADD?#neuromodulators?#THC?#dronabinol?#marinol?#ampakines?#gabakines?#CX1739?#CX717?#KRMII81?#SCI?#OSA?#spinalcordinjury?#Psychiatric?#biotechnology?#epilepsy #neuropathicpain #ADHD #jeffmargolis #OTCmarkets #RSPI #pennystocks #arnoldlippa #apnoea
-
RespireRx Press Release - KRM-II-81 for Epilepsy #pharmaceuticals?#lifesciences?#biotech? #respirerx?#healthcareinnovation?#healthcare?#cannabinoids?#pharmaceuticals?#pharma?#CNS?#epilepsy?#pain?#neurology?#sleep?#apnea?#obstructivesleepapnea?#ADHD?#ADD?#neuromodulators?#THC?#dronabinol?#marinol?#ampakines?#gabakines?#CX1739?#CX717?#KRMII81?#SCI?#OSA?#spinalcordinjury?#Psychiatric?#biotechnology?#epilepsy #neuropathicpain #ADHD #jeffmargolis #OTCmarkets #RSPI #pennystocks #arnoldlippa #apnoea
-
RespireRx Pharmaceuticals Inc.: A Biopharmaceutical Company转发了
RespireRx Pharmaceuticals Inc.: A Biopharmaceutical Company (OTC:RSPI) said a case study demonstrating positive results from the treatment of an epilepsy patient involving its therapeutic KRM-II-81 has been published in a peer-reviewed journal. The company said that the 19-year-old patient in the case study had pharmaco-resistant epilepsy and required a craniotomy to remove the brain tissue generating seizures. Cortical brain tissue surgically resected from the patient exhibited epileptiform bursting with microelectrode recordings but once KRM–II–81, one of RespireRX’s GABAkines, was added to the incubation fluid, the epileptiform activity in the excised brain tissue was fully suppressed, the company highlighted.? A year after the surgery, the patient remains seizure-free but on medication. More at #Proactive #ProactiveInvestors #OTC #RSPI https://ow.ly/PwO21057PZT
-
RSPI Press Release - RespireRx Hires Will Clodfelter as part-time SVP Business Development #pharmaceuticals?#lifesciences?#biotech? #respirerx?#healthcareinnovation?#healthcare?#cannabinoids?#pharmaceuticals?#pharma?#CNS?#epilepsy?#pain?#neurology?#sleep?#apnea?#obstructivesleepapnea?#ADHD?#ADD?#neuromodulators?#THC?#dronabinol?#marinol?#ampakines?#gabakines?#CX1739?#CX717?#KRMII81?#SCI?#OSA?#spinalcordinjury?#Psychiatric?#biotechnology?#epilepsy #neuropathicpain #ADHD #jeffmargolis #OTCmarkets #RSPI #pennystocks Your document has finished loading